Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$160.85
-0.5%
$173.42
$130.96
$182.89
$284.81B0.615.66 million shs5.90 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$149.92
-0.8%
$154.44
$143.13
$175.97
$361.27B0.557.48 million shs8.33 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$128.26
-0.4%
$126.49
$99.14
$133.10
$324.89B0.398.26 million shs7.42 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.70
+1.9%
$26.88
$25.20
$40.37
$156.85B0.6342.88 million shs63.86 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.54%-3.84%-10.99%-4.65%+7.77%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.82%+2.11%-4.95%-4.27%-7.95%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.43%-1.87%-1.60%+1.50%+8.49%
Pfizer Inc. stock logo
PFE
Pfizer
+1.95%+9.66%+0.54%+2.90%-27.96%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.8117 of 5 stars
2.43.04.23.93.12.52.5
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.928 of 5 stars
3.23.04.23.93.72.51.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.7428 of 5 stars
2.33.03.34.13.22.52.5
Pfizer Inc. stock logo
PFE
Pfizer
4.977 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$174.318.37% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8617.30% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.332.40% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.0029.96% Upside

Current Analyst Ratings

Latest JNJ, MRK, ABBV, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$195.00 ➝ $187.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$195.00 ➝ $180.00
4/26/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$142.00 ➝ $143.00
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.24$15.65 per share10.28$5.78 per share27.83
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.24$14.17 per share10.58$28.57 per share5.25
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.40$3.02 per share42.48$14.85 per share8.64
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.68$3.22 per share8.61$15.81 per share1.75

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3747.7313.332.0411.02%165.18%14.40%7/25/2024 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.3513.722.3845.26%36.43%15.01%7/18/2024 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.90142.5112.941.653.76%14.15%5.24%8/6/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3676.9410.111.153.62%10.88%4.91%8/6/2024 (Estimated)

Latest JNJ, MRK, ABBV, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/26/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion    
4/25/2024Q1 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.94$2.07+$0.13$2.27$15.21 billion$15.78 billion    
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.85%+7.84%183.98%52 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.18%+5.70%29.68%63 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.40%+6.08%342.22%13 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.06%+2.57%466.67%15 Years

Latest JNJ, MRK, ABBV, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

JNJ, MRK, ABBV, and PFE Headlines

SourceHeadline
Fifth Third Bancorp Reduces Position in Pfizer Inc. (NYSE:PFE)Fifth Third Bancorp Reduces Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 3 at 12:41 AM
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid declinePfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
msn.com - May 2 at 9:58 PM
Pfizer Prospects Garner Mixed Sentiment From Analysts: Finally, The Pivot Investors Have Been Waiting ForPfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
markets.businessinsider.com - May 2 at 9:58 PM
Pfizer (NYSE:PFE) Announces Quarterly  Earnings ResultsPfizer (NYSE:PFE) Announces Quarterly Earnings Results
marketbeat.com - May 2 at 4:04 PM
Pfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected EarningsPfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected Earnings
marketbeat.com - May 2 at 2:47 PM
Pfizer (NYSE:PFE) Price Target Raised to $29.00Pfizer (NYSE:PFE) Price Target Raised to $29.00
marketbeat.com - May 2 at 1:32 PM
Pfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call TranscriptPfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 2 at 1:30 PM
BMO Capital Markets Reiterates "Outperform" Rating for Pfizer (NYSE:PFE)BMO Capital Markets Reiterates "Outperform" Rating for Pfizer (NYSE:PFE)
marketbeat.com - May 2 at 11:13 AM
Pfizer Stock: Finally The Market Is Waking UpPfizer Stock: Finally The Market Is Waking Up
seekingalpha.com - May 2 at 8:29 AM
3 Contrarian Stocks That Could Make You a Fortune (If You Dare)3 Contrarian Stocks That Could Make You a Fortune (If You Dare)
investorplace.com - May 2 at 7:22 AM
My Top 5 Favorite High-Yield Dividend Stocks to Buy in MayMy Top 5 Favorite High-Yield Dividend Stocks to Buy in May
fool.com - May 2 at 5:50 AM
Pfizers Stock Is a Buy. Here Are Six Reasons Why.Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
fool.com - May 2 at 5:15 AM
Q1 2024 Pfizer Inc Earnings Call TranscriptQ1 2024 Pfizer Inc Earnings Call Transcript
gurufocus.com - May 2 at 1:01 AM
Raymond James Financial Services Advisors Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)Raymond James Financial Services Advisors Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 1 at 11:16 PM
Pfizer stock gains 7% after earnings beat, company calls dividend securePfizer stock gains 7% after earnings beat, company calls dividend 'secure'
msn.com - May 1 at 8:39 PM
Pfizer (PFE) Q1 2024 Earnings Call TranscriptPfizer (PFE) Q1 2024 Earnings Call Transcript
fool.com - May 1 at 8:39 PM
Why Pfizer Stock Blasted More Than 6% Higher TodayWhy Pfizer Stock Blasted More Than 6% Higher Today
fool.com - May 1 at 5:55 PM
PFE Earnings: Pfizer Rises After Smashing Q1 EstimatesPFE Earnings: Pfizer Rises After Smashing Q1 Estimates
msn.com - May 1 at 3:39 PM
Pfizer (NYSE:PFE) Stock Price Up 3.8%Pfizer (NYSE:PFE) Stock Price Up 3.8%
marketbeat.com - May 1 at 1:59 PM
Pfizer Stock Gets Boost From Better-Than-Expected EarningsPfizer Stock Gets Boost From Better-Than-Expected Earnings
investopedia.com - May 1 at 1:46 PM
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance RaisedPfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
zacks.com - May 1 at 12:46 PM
Pfizer raises guidance amid cost savingsPfizer raises guidance amid cost savings
msn.com - May 1 at 10:38 AM
Pfizer Stock Rises as Outlook Rises After Earnings BeatPfizer Stock Rises as Outlook Rises After Earnings Beat
finance.yahoo.com - May 1 at 10:38 AM
Pfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue DeclinePfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
finance.yahoo.com - May 1 at 10:38 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.